Literature DB >> 1827928

In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease.

G Mantzaris1, D P Jewell.   

Abstract

A single dose of a synthetic peptide of A gliadin (residues 206-217) sharing homology with the E1b protein of adenovirus 12 was instilled intraduodenally in two treated coeliac patients. Biopsy specimens were taken before and repeatedly up to 24 h after the instillation by means of a Quinton hydraulic multiple biopsy instrument and processed for histology, morphometry (intraepithelial lymphocyte counts, crypt-to-villus ratio), immunocytochemistry, electron microscopy, and disaccharidase assays. Two subjects with irritable bowel syndrome served as controls. In the coeliac group disaccharidase activities decreased at 24 h, and abnormalities were seen on light and electron microscopy and in morphometric measurements. The lamina propria became infiltrated with mononuclear cells after 2 h, and there was also a rise in IgA-containing cells in one patient. No such abnormalities were seen in the control group. The serum concentrations of C3, C4, and C1 esterase inhibitor remained unchanged. Thus, the dodecapeptide may be one epitope of gliadin mediating the pathogenesis of coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827928     DOI: 10.3109/00365529108996500

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  16 in total

Review 1.  Molecular mimicry in autoimmune disease.

Authors:  S Leech
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 2.  The immunology of coeliac disease.

Authors:  G J Mantzaris; W M Rosenberg; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

3.  The molecular diversity of α-gliadin genes in the tribe Triticeae.

Authors:  Peng-Fei Qi; Qing Chen; Thérèse Ouellet; Zhao Wang; Cheng-Xing Le; Yu-Ming Wei; Xiu-Jin Lan; You-Liang Zheng
Journal:  Genetica       Date:  2013-07-27       Impact factor: 1.082

4.  The changing face of celiac disease.

Authors:  R Lad; K Jacobson
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

5.  Coeliac disease: A review of the causative agents and their possible mechanisms of action.

Authors:  H J Cornell
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

6.  Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease.

Authors:  W Dieterich; B Esslinger; D Trapp; E Hahn; T Huff; W Seilmeier; H Wieser; D Schuppan
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

7.  Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin.

Authors:  M ten Dam; Y Van De Wal; M L Mearin; Y Kooy; S Peña; J W Drijfhout; F Koning; M Van Tol
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin.

Authors:  Y van de Wal; Y M Kooy; P A van Veelen; S A Peña; L M Mearin; O Molberg; K E Lundin; L M Sollid; T Mutis; W E Benckhuijsen; J W Drijfhout; F Koning
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  Coeliac disease: characterisation of monoclonal antibodies raised against a synthetic peptide corresponding to amino acid residues 206-217 of A-gliadin.

Authors:  H J Ellis; A P Doyle; R P Sturgess; P J Ciclitira
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

10.  A catalogue of Triticum monococcum genes encoding toxic and immunogenic peptides for celiac disease patients.

Authors:  Patrizia Vaccino; Heinz-Albert Becker; Andrea Brandolini; Francesco Salamini; Benjamin Kilian
Journal:  Mol Genet Genomics       Date:  2008-12-23       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.